Paul Agapow, Director Oncology R&D at AstraZeneca

AI & ML has been remarkably successful in many industries and domains, so it is only natural that the pharmaceutical industry is adopting data-centric approaches at speed. However, the nature of drug development means that it far from ‘just’ another data problem. Here I outline it’s unique aspects that raise challenges to AI and require adept use of data, ML technology and subject expertise.